Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice.

# SUMMARY:

                        The Food and Drug Administration (FDA) is announcing an amendment to the notice of a meeting of the Anti-Infective Drugs Advisory Committee. This meeting was announced in the                         **Federal Register**                         of July 25, 2006 (71 FR 42096). The amendment is being made to reflect a change in the                         *Date and Time*                         and                         *Agenda*                         portions of the document. The meeting scheduled for September 11, 2006, has been cancelled. There are no other changes.                     

# FOR FURTHER INFORMATION CONTACT:

                        Sohail Mosaddegh, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail:                         *sohail.mosaddegh@fda.hhs.gov*, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington DC area), code 3014512530. Please call the Information Line for up-to-date information on this meeting.                    

# SUPPLEMENTARY INFORMATION:

                    In the                     **Federal Register**                     of July 25, 2006 (71 FR 42096), FDA announced that a meeting of the Anti-Infective Drugs would be held on September 11 and 12, 2006. On page 42096, in the second column, the                     *Date and Time*                     portion of the meeting is amended to read as follows:                

*Date and Time*: The meeting will held on September 12, 2006, from 8 a.m. to 5 p.m.                

                    On page 42096, third column, the                     *Agenda*                     portion of the meeting is amended to read as follows:                

*Agenda*: On September 12, 2006, the committee will discuss supplemental new drug application (sNDA) 21-158/S-006, FACTIVE (gemifloxacin mesylate) Tablets, submitted by Oscient Pharmaceuticals Corp., for the proposed treatment of acute baterial sinusitis.                

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Dated: August 25, 2006.

Randall W. Lutter,

Associate Commissioner for Policy and Planning.

[FR Doc. 06-7310 Filed 8-30-06; 8:45 am]

BILLING CODE 4160-01-S